J. Harold Helderman, William M. Bennett, Diane M. Cibrik, Dixon B. Kaufman, Andrew Klein, Steven K. Takemoto,
... those who did receive induction therapy, most received muromonab-CD3 (OKT3®). The use of induction therapy gradually increased ... by which time 59% of recipients received induction. Muromonab-CD3 was the predominant immunosuppressive agent used for induction ... 2001, an increase from its introduction in 1999. Muromonab-CD3 use has dropped to <1% of transplants, and ... in 1992. Of the episodes requiring antilymphocyte therapy, muromonab-CD3 was the predominant agent used through 1998, with ... patients, compared to 16% of patients treated with muromonab-CD3. Although daclizumab and basiliximab are neither approved nor ...
Tópico(s): Organ and Tissue Transplantation Research
2003 - Elsevier BV | American Journal of Transplantation
Pariwat Thaisetthawatkul, Arie Weinstock, Susan L. Kerr, Michael E. Cohen,
Muromonab-CD3 is widely used for immunosuppression in patients undergoing solid organ transplant. We report two siblings with ... renal disease who developed encephalopathy and seizures from muromonab-CD3 following renal transplant. The first case is a ... encephalopathy, seizure, and triparesis following renal transplant while muromonab-CD3 was used for immunosuppression. The second case was ... developed recurrent focal seizures while she was on muromonab-CD3 for renal transplant immunosuppression. In both cases, a ...
Tópico(s): Neurological and metabolic disorders
2001 - SAGE Publishing | Journal of Child Neurology
Michelle I. Wilde, Karen L. Goa,
The murine monoclonal antibody muromonab CD3 (0KT3) is directed against the CD3 antigen on peripheral human T cells and effectively blocks all T cell function. Prophylaxis with muromonab CD3 (5mg intravenously once daily for 10 to 14 ... inconsistencies in trial design and trial size), prophylactic muromonab CD3-based sequential therapy is significantly more effective than ... survival have been observed. The overall efficacy of muromonab CD3- and polyclonal-based prophylactic regimens appears to be ... regimen improved graft and patient survival compared with muromonab CD3-based prophylaxis in hepatic transplant recipients. Antimuromonab CD3 ...
Tópico(s): T-cell and B-cell Immunology
1996 - Adis, Springer Healthcare | Drugs
Raafat Seifeldin, Kenneth Lawrence, A F Rahamtulla, A P Monaco,
... cases of seizures associated with the use of muromonab-CD3. CASE SUMMARY: TWO uremic cadaveric kidney transplant recipients had developed generalized seizures following administration of muromonab-CD3 within the first 2 days after transplantation. Seizures were treated successfully with intravenous phenytoin, and muromonab-CD3 administration was discontinued. DISCUSSION: The overall frequency of seizures during muromonab-CD3 administration is 6%. Uremia in patients in the ... transplant suggest that they had been induced by muromonab-CD3 administration. The mechanism of how this could have ...
Tópico(s): Neurological Complications and Syndromes
1997 - SAGE Publishing | Annals of Pharmacotherapy
Dixon B. Kaufman, Ron Shapiro, Michael R. Lucey, Wida S. Cherikh, Rami Bustami, D.B. Dyke,
... in the type of antibody preparation (Figure 1). Muromonab-CD3 (OKT3® Orthobiotech, Bridgewater, NJ), which peaked in use ... at 21% in 1993, has disappeared from practice. Muromonab-CD3, which peaked at 44% in 1993, is now ... have changed dramatically (Figure 5), so that while muromonab-CD3 was used in 56% of patients in 1995, ... and again the type of agents changed from muromonab-CD3 and equine antilymphoblast globulin (61% and 25%, respectively, in 1992) to rabbit antithymocyte globulin and muromonab-CD3 (accounting for 17% and 12% of patients, respectively, ...
Tópico(s): Transplantation: Methods and Outcomes
2004 - Elsevier BV | American Journal of Transplantation
Samantha Zaroff, Grace Min Yi Tan,
... few US FDA-approved mAb therapeutics, such as muromonab-CD3, were generated solely in mice, it became evident ... undergo humanization [8–10]. Since the approval of muromonab-CD3 in 1986, the FDA has approved approximately 80 ... Scholar8. Smith SL. Ten years of orthoclone OKT3 (muromonab-CD3): a review. J. Transpl. Coord. 6(3), 109– ...
Tópico(s): CAR-T cell therapy research
2019 - Future Science Ltd | BioTechniques
Muhammad Chaudhry, Adrian J. Correa, Christopher S. Lee, Andrew J. Yoon, Luanda Grazette, Farhood Saremi, Michael Fong,
... management of GCM has included the use of muromonab-CD3, pulse steroids, and varying combinations of azathioprine, cyclosporine, ... toxicity, such as the cytokine release syndrome with muromonab-CD3. There are case reports detailing the use of ... high dose steroids and azathioprine and 9 with muromonab-CD3. There was a 5% mortality rate at 1 ...
Tópico(s): Whipple's Disease and Interleukins
2014 - Elsevier BV | International Journal of Cardiology
Ian N. Foltz, Margaret Karow, Scott M. Wasserman,
... technique.4,5 In 1986, the first mAb, muromonab-CD3, was approved5 for treating steroid-resistant acute allograft ... been withdrawn from the US market. Four agents—muromonab-CD3 and daclizumab (both for commercial reasons), efalizumab (for ... use in cardiology include the aforementioned fully murine muromonab-CD3, the chimeric anti-glycoprotein IIb/IIIa antigen-binding ...
Tópico(s): Transgenic Plants and Applications
2013 - Lippincott Williams & Wilkins | Circulation
Luit Penninga, Christian H. Møller, Elisabeth I Penninga, Martin Iversen, Christian Gluud, Daniel A. Steinbrüchel,
... induction with ATG, ALG, IL‐2RA, alemtuzumab, or muromonab‐CD3 for lung transplant recipients. Search methods We searched ... study, 25 participants); polyclonal T‐cell antibody versus muromonab‐CD3 (1 study, 64 participants); and polyclonal T‐cell ... in one study that compared antithymocyte globulin versus muromonab‐CD3 relating to adverse events (25/34 (74%) versus ...
Tópico(s): Viral Infections and Immunology Research
2013 - Elsevier BV | Cochrane library
Miquel Lozano, Federico Oppenheimer, Frederic Cofán, Laura Rosinyol, Roberto Mazzara, Ginés Escolar, Antonio Ordinas,
Background: Muromonab-CD3 is a murine monoclonal antibody (MoAb) that is used in the prophylaxis and treatment of acute graft ... and methods: We have studied the effect of muromonab-CD3 infusion on platelets using flow cytometry in six patients who received three daily doses of muromonab-CD3 as prophylaxis of rejection before receiving a living ... were collected before, 15 and 60 min after muromonab-CD3 infusion. Immunolabeling of platelets was performed in whole ... Becton Dickinson, Mountain View, CA, USA). Results: After muromonab-CD3 infusion, an increase in the binding of MoAb ...
Tópico(s): Renal Transplantation Outcomes and Treatments
2001 - Elsevier BV | Thrombosis Research
Muriel L Burk, Karl Matuszewski,
... literature for the practical and efficient use of muromonab-CD3 (OKT-3) and antithymocyte globulin (ATG) in renal ... Key words used were antithymocyte globulin (ATG, Atgam), muromonab-CD3 (OKT-3, Orthoclone), and kidney transplantation. Thereafter, the ...
Tópico(s): Blood groups and transfusion
1997 - SAGE Publishing | Annals of Pharmacotherapy
Simran Thakkar, Aditi Chopra, Lakshmi Nagendra, Sanjay Kalra, Saptarshi Bhattacharya,
... exhibited the most promising preclinical and clinical results. Muromonab-CD3, which also happened to be a murine CD3 ... for graft rejection. The adverse effects associated with muromonab-CD3 led to its withdrawal. Teplizumab, a newer CD3 ...
Tópico(s): Pancreatic function and diabetes
2023 - | touchREVIEWS in Endocrinology
Charles Panackel, Joe F. Mathew, Mohamed Fawas N, Mathew Jacob,
... as well as NK cells, monocytes and thymocytes Muromonab-CD3 (OKT3)Anti-CD3-specific antibody causing T-cell ... depleting agents [polyclonal – ATGs, monoclonal – alemtuzumab (Campath – 1H), muromonab-CD3 (OKT3)], and non-depleting agents [interleukin 2 receptor ...
Tópico(s): Liver Disease and Transplantation
2022 - Elsevier BV | Journal of Clinical and Experimental Hepatology
Massimo Baraldo, Giorgia Gregoraci, Ugolino Livi,
... 10 AZA, azathioprine; CSs, corticosteroids; Cyc, cyclosporine; OKT3, muromonab-CD3; SFG, steroid-free group; SG, steroid group; MMF, ... Cyc, cyclosporine; CSs, corticosteroids; MMF, mycophenolate mofetil; OKT3, muromonab-CD3; SFM, steroid-free maintenance group; SG, steroid group; ...
Tópico(s): Mechanical Circulatory Support Devices
2014 - Springer Science+Business Media | Transplant International
... the introduction of the first mAb-based drug, muromonab-CD3 (orthoclone OKT3) [1], over 20 mAb therapeutics have ... Bibliography1 Smith SL. Ten years of orthoclone OKT3 (muromonab-CD3): a review. J. Transpl. Coord.6(3),109– ...
Tópico(s): Protein purification and stability
2011 - Future Science Ltd | Bioanalysis
Noboru Oda, Tomoko Kato, Kazuo Komamura, Akihisa Hanatani, Akiko Mano, Kazuhiko Hashimura, Masanori Asakura, Kazuo Niwaya, Toshihiro Funatsu, Junjiro Kobayashi, Kyoichi Wada, Shuji Hashimoto, Hatsue Ishibashi‐Ueda, Yukiko Nakano, Yasuki Kihara, Masafumi Kitakaze,
... ISHLT Registry, except for more frequent use of Muromonab-CD3 (26.9% versus 3.3%, P < 0.0001) ... for induction therapy has been recently changed from Muromonab-CD3 to Basiliximab. The incidences of post-HTx hypertension, ...
Tópico(s): Renal Transplantation Outcomes and Treatments
2010 - Japanese Heart Journal Assoc | International Heart Journal
Junchao Cai, Paul I. Terasaki,
... era, 1987 to 1993, when antilymphocyte globulin and muromonab-CD3 were the major agents; (2) a high-induction, ... antithymocyte globulin (rATG; 1999) replaced antilymphocyte globulin and muromonab-CD3, with maintenance agents also used; (3) the high- ...
Tópico(s): Transplantation: Methods and Outcomes
2010 - Wolters Kluwer | Transplantation
Satoshi Yokoyama, Mureo Kasahara, Akinari Fukuda, Shuichi Sato, Tetsuya Mori, Atsuko Nakagawa, Akira Matsui,
... hepatic artery of the graft were flushed with muromonab-CD3 (Orthoclone OKT3) contained in a histidine-tryptophan-ketoglutarate ... reduce the number of donor-derived passenger lymphocytes, muromonab-CD3 was used for graft perfusion just after harvesting. ...
Tópico(s): Renal Transplantation Outcomes and Treatments
2008 - Wolters Kluwer | Transplantation
Ana Campos, E. Lage, R. Hinojosa, Antonio Ordóñez, José Miguel Cisneros, Soledad Cabezón, Sílvia Gómez, A. Aguilera, Eduardo Arana‐Rueda, Aurelio Cayuela,
... cardiac transplantation at our center. Thirty patients received muromonab-CD3 (OKT3, Janssen-Cilag, The Netherlands) as the induction ...
Tópico(s): Viral Infections and Immunology Research
2005 - Elsevier BV | Transplantation Proceedings
Michael R. Go, Ginny L. Bumgardner,
The introduction of OKT3 (muromonab-CD3) revolutionized the management of steroid-resistant rejection in transplant patients. Indeed, after the success of OKT3 for treatment of rejection, ...
Tópico(s): Drug-Induced Hepatotoxicity and Protection
2002 - Wolters Kluwer | Transplantation
John M. Costello, Elfriede Pahl,
... immunosuppression. Critically ill patients may additionally benefit from muromonab-CD3 (OKT3) to augment lympholysis. Treatment employed specifically for ... addition to corticosteroids, cyclophosphamide and antithymocyte globulin or muromonab-CD3, along with plasmapheresis, may improve survival. Systemic heparinization ...
Tópico(s): Cardiac Structural Anomalies and Repair
2002 - Adis, Springer Healthcare | Pediatric Drugs
Robert J. Berkowitz, Carl J. Possidente, Bruce R. McPherson, Ann Guillot, Stuart V. Braun, Jeffrey Reese,
Muromonab‐CD3 (OKT3), a murine IgG2a antibody directed against the T3 (CD3) complex on mature lymphocytes, triggers adverse ...
Tópico(s): Mast cells and histamine
2000 - Wiley | Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy
Stephanie M. Levine, Luis F. Angel, Antonio Anzueto, Irawan Susanto, Jay I. Peters, Edward Y. Sako, Charles L. Bryan,
... EBV) infection and the use of immunosuppression, particularly muromonab-CD3 (OKT3)(Orthoclone OKT-3; Ortho Biotech; Raritan, NJ). ... EBV) infection and the use of immunosuppression, particularly muromonab-CD3 (OKT3)(Orthoclone OKT-3; Ortho Biotech; Raritan, NJ). ...
Tópico(s): Eosinophilic Disorders and Syndromes
1999 - Elsevier BV | CHEST Journal
Brian G. Weinshenker, Brenda H. Bass, George C. Ebers, George P. Rice,
... old woman received a 10-day treatment with muromonab-CD3 (Orthoclone OKT3) (total dose 50 mg) as part ...
Tópico(s): Dermatology and Skin Diseases
1989 - Elsevier BV | Journal of the American Academy of Dermatology
Daisuke Ueda, Tomohide Hori, Justin H. Nguyen, Shinji Üemoto,
... significant factors for the introduction of therapy with muromonab‐CD3 (MCD3) after LT. Methods A total of 1415 ...
Tópico(s): Renal Transplantation Outcomes and Treatments
2010 - Wiley | Journal of Hepato-Biliary-Pancreatic Sciences
Alain Beck, Christine Nowak, Deborah Meshulam, Kristina Reynolds, David Chen, Dennis B. Pacardo, Samantha B. Nicholls, Gregory J. Carven, Zhenyu Gu, Jing Fang, Dongdong Wang, Amit Katiyar, Xiang Tao, Hongcheng Liu,
... of the anti-CD3 recombinant monoclonal antibody (mAb), muromonab-CD3, a mouse antibody for the prevention of transplant ...
Tópico(s): Viral Infectious Diseases and Gene Expression in Insects
2022 - Multidisciplinary Digital Publishing Institute | Antibodies
Navid Shomali, Behzad Baradaran, Amin Daei Sorkhabi, Aila Sarkesh, Mohammad Saeed Kahrizi, Foad Tosan, Ata Mahmoodpoor, Amirhossein Mardi, Hamed Mohammadi, Ali Hassanzadeh, Hossein Saeedi, Mehrzad Hajialilo, Maryam Hemmatzadeh, Faroogh Marofi, Siamak Sandoghchian Shotorbani,
... were co-cultured with interleukin (IL)-2 and muromonab-CD3 (OKT-3) for active-induced cell death (AICD) ...
Tópico(s): Inflammasome and immune disorders
2022 - Elsevier BV | Gene
Zeng Wang, Guoqing Wang, Huaqing Lu, Hongjian Li, Mei Tang, Aiping Tong,
Abstract Since the first monoclonal antibody drug, muromonab-CD3, was approved for marketing in 1986, 165 antibody drugs have been approved or are under regulatory review worldwide. With the approval of new ...
Tópico(s): Biosimilars and Bioanalytical Methods
2022 - Springer Nature | Molecular Biomedicine
Pardis Mokhtary, Zeinab Pourhashem, Akram Abouei Mehrizi, Claudia Sala, Rino Rappuoli,
... infectious disease management. Since the first therapeutic mAb, muromonab-CD3, was approved by the U.S. Food and ...
Tópico(s): Virus-based gene therapy research
2022 - Multidisciplinary Digital Publishing Institute | Biomedicines
Silvia Stefánia Longoni, Natalia Tiberti, Zeno Bisoffi, Chiara Piubelli,
... for infectious diseases. The first monoclonal antibody (mAb), Muromonab CD3, was introduced for the prevention of kidney transplant ...
Tópico(s): Trypanosoma species research and implications
2021 - Frontiers Media | Frontiers in Medicine